Table VII.
Effect of the MDR1 C3435T genotype on amlodipine plasma concentration (C) and efficacy.
| Genotype | P-value | ||||||
|---|---|---|---|---|---|---|---|
| Variables | CC (n=30) | CT (n=24) | TT (n=6) | CC vs. CT | CC vs. TT | CT vs. TT | ANOVA |
| C, ng/ml | |||||||
| C0 | 7.40±3.38 | 7.49±3.54 | 5.70±1.59 | 0.93 | 0.33 | 0.33 | 0.61 |
| C2 | 9.13±4.79 | 9.39±2.95 | 5.74±3.63 | 0.82 | 0.11 | 0.02 | 0.14 |
| C6 | 11.26±4.78 | 11.32±4.13 | 6.96±4.43 | 0.96 | 0.05 | 0.03 | 0.09 |
| C24 | 7.35±3.43 | 7.43±3.08 | 6.20±3.86 | 0.77 | 0.39 | 0.46 | 0.66 |
| BP (mmHg) | |||||||
| Δ SBP | 18±9 | 18±10 | 17±15 | 0.97 | 0.86 | 0.85 | 0.96 |
| Δ DBP | 6±5 | 8±6 | 10±11 | 0.13 | 0.46 | 0.78 | 0.25 |
| Efficiency, % | 50.00 | 54.17 | 66.67 | 0.76 | 0.46 | 0.58 | 0.75 |
MDR1, multidrug resistance protein 1; ANOVA, analysis of variance; C0, C at 4 weeks; C2, 2 h after the last dose at 4 weeks; C6, 6 h; C24, 24 h; BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure.